RECOMBINANT HUMAN GROWTH-HORMONE TREATMENT OF CHILDREN FOLLOWING RENAL-TRANSPLANTATION

被引：49

作者：

FINE, RN

YADIN, O

NELSON, PA

PYKEGRIMM, K

BOECHAT, MI

LIPPE, BH

SHERMAN, BM

ETTENGER, RB

KAMIL, E

机构：

[1] Department of Pediatrics, UCLA Center for the Health Sciences, Los Angeles, 90024, CA

[2] Division of Pediatric Nephrology, UCLA Center for the Health Sciences, Los Angeles, 90024, CA

[3] Department of Radiology, UCLA Center for the Health Sciences, Los Angeles, 90024, CA

[4] Division Endocrinology, UCLA Center for the Health Sciences, Los Angeles, 90024, CA

[5] Genentech, South San Francisco, 94 080, CA

来源：

PEDIATRIC NEPHROLOGY | 1991年 / 5卷 / 01期

关键词：

RECOMBINANT HUMAN GROWTH HORMONE; GROWTH RETARDATION; RENAL ALLOGRAFT RECIPIENTS;

D O I：

10.1007/BF00852873

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Nine growth-retarded renal allograft recipients received either thrice weekly or daily subcutaneous recombinant human growth hormone (rhGH) for 6-30 months. The annualized growth velocity for the initial year of rhGH treatment was significantly greater than that of the preceding year (2.5 +/- 2.1 vs 5.7 +/- 2.7; P < 0.0001). There was no advancement in bone age greater than the increase in chronological age, no significant increase in the mean fasting serum glucose or insulin levels, nor significant decrease in the calculated creatinine clearance following rhGH treatment. However, two patients experienced rejection episodes following rhGH treatment indicating the potiental adverse consequences of the treatment on allograft function. This will require further delineation in prospective controlled studies. The serum insulin-like growth factor-1 levels significantly increased at 6 months (P < 0.009) and 12 months (P < 0.002) following rhGH treatment compared with baseline values. These preliminary data indicate that rhGH treatment may be effective in improving the growth velocity of growth-retarded renal allograft recipients.

引用

页码：147 / 151

页数：5

共 20 条

[1] Fine R.N., Growth in children with renal insufficiency, Clinical dialysis, pp. 661-670, (1984)
[2] Kleinknecht C., Broyer M., Huot D., Marti-Hennenberg C., Darois A.M., Growth and development of nondialyzed children with chronic renal failure, Kidney Int, pp. 40-47, (1983)
[3] Potter D.E., Comparison of CAPD and hemodialysis in children, Chronic ambulatory peritoneal dialysis (CAPD) and chronic cycling peritoneal dialysis (CCPD) in children, pp. 297-306, (1987)
[4] Chantler C., Broyer M., Donckerwolcke R.A., Bryner H., Brunner F.P., Jacobs C., Kramer P., Selwood N.H., Wing A.J., Growth and rehabilitation of long-term survivors of treatment for end-stage renal failure in childhood, Proc Eur Dial Transplant Assoc, 18, pp. 329-342, (1981)
[5] Potter D., Feduska N., Nelzer J., Garovoy M., Hopper S., Duca R., Salvatierra O., Twenty years of renal transplantation in children, Pediatrics, 77, pp. 465-470, (1986)
[6] van Diemen-Steenvoorde R., Donckerwolcke R.A., Brackel H., Wolff E.D., de Jong M.C.J.W., Growth and sexual maturation in children after kidney transplantation, J Pediatr, 110, pp. 351-356, (1987)
[7] Mehls O., Ritz E., Skeletal growth in experimental uremia, Kidney Int, pp. S33-S62, (1983)
[8] Mehls O., Ritz E., Hunziker E.E., Eggli P., Heinrich U., Zapf J., Improvement of growth and food utilization by human recombinant growth hormone in uremia, Kidney Int, 33, pp. 45-52, (1988)
[9] Koch V., Lippe B.M., Nelson P.A., Boechat M.I., Sherman B.M., Fine R.N., Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure, J Pediatr, 115, pp. 365-371, (1989)
[10] Fine R.N., Koch V.H., Nelson P.A., Boechat M.I., Fine S.E., Sherman B.M., Lippe B.H., Recombinant human growth hormone (rhGH) treatment of children with renal insufficiency, Adv Nephrol, 19, pp. 187-208, (1990)

← 1 2 →